Pia Vahteristo Selected Research

Hereditary leiomyomatosis and renal cell cancer

1/2022	Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas.
11/2021	Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology.
1/2016	MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
11/2013	MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
6/2010	No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.
7/2009	Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pia Vahteristo Research Topics

Disease

19	Neoplasms (Cancer) 01/2023 - 08/2002
17	Leiomyoma (Uterine Fibroids) 01/2023 - 10/2011
6	Hereditary leiomyomatosis and renal cell cancer 01/2022 - 07/2009
5	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 06/2006
5	Pituitary Neoplasms (Pituitary Adenoma) 10/2008 - 05/2006
4	Breast Neoplasms (Breast Cancer) 01/2011 - 08/2002
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2008
2	Endometrial Neoplasms (Endometrial Cancer) 01/2021 - 02/2006
2	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 06/2006
2	Stomach Neoplasms (Stomach Cancer) 09/2015 - 06/2015
2	Leiomyomatosis 06/2012 - 06/2008
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 11/2021
1	Carcinogenesis 01/2021
1	Atherosclerosis 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019
1	Adenomyoma 01/2018
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2017
1	Intellectual Disability (Idiocy) 02/2016
1	alpha-Thalassemia 02/2016
1	Phyllodes Tumor (Cystosarcoma Phylloides) 01/2016
1	Fibroadenoma 01/2016
1	Ewing Sarcoma (Sarcoma, Ewing) 09/2015
1	Chromosome Aberrations (Chromosome Abnormalities) 02/2014
1	Microsatellite Instability 09/2013
1	Lymphoma (Lymphomas) 04/2013
1	Ataxia Telangiectasia (Louis Bar Syndrome) 07/2011
1	Hodgkin Disease (Hodgkin's Disease) 07/2011
1	Heterotaxy Syndrome 07/2010
1	Carcinoid Tumor (Carcinoid) 08/2007
1	Hyperparathyroidism 08/2007
1	Adenoma (Adenomas) 06/2006
1	Familial Breast Cancer 02/2005
1	Li-Fraumeni Syndrome 08/2002

Drug/Important Bio-Agent (IBA)

12	Mediator ComplexIBA 01/2023 - 10/2011
11	Fumarate Hydratase (Fumarase)IBA 01/2023 - 06/2008
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2002
5	ParaffinIBA 01/2023 - 07/2009
5	Formaldehyde (Formol)FDA Link 01/2023 - 07/2009
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2011
4	aryl hydrocarbon receptor-interacting proteinIBA 10/2008 - 05/2006
3	RNA (Ribonucleic Acid)IBA 01/2023 - 12/2020
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2016
3	Phosphotransferases (Kinase)IBA 11/2018 - 08/2002
2	Calcibiotic Root Canal SealerIBA 01/2018 - 08/2014
2	NucleotidesIBA 01/2017 - 09/2015
2	Nonsense Codon (Nonsense Mutation)IBA 01/2017 - 02/2016
2	Cyclin CIBA 01/2016 - 05/2014
2	RNA Polymerase II (RNA Polymerase B)IBA 01/2016 - 05/2014
2	Poly TIBA 09/2015 - 02/2011
2	DNA (Deoxyribonucleic Acid)IBA 07/2009 - 02/2005
1	AntibodiesIBA 01/2022
1	Apoptosis Regulatory ProteinsIBA 11/2021
1	ChromatinIBA 01/2021
1	ChemokinesIBA 01/2019
1	CytokinesIBA 01/2019
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2018
1	HMGA2 ProteinIBA 01/2018
1	L-Aminoadipate-Semialdehyde DehydrogenaseIBA 01/2017
1	Collagen Type IV (Type IV Collagen)IBA 02/2016
1	FumaratesIBA 02/2016
1	X-linked Nuclear ProteinIBA 02/2016
1	Leucine (L-Leucine)FDA Link 01/2016
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2016
1	3' Untranslated Regions (3' UTR)IBA 09/2015
1	Cadherins (E-Cadherin)IBA 06/2015
1	Insulin (Novolin)FDA Link 06/2015
1	CateninsIBA 06/2015
1	integrin alpha7beta1IBA 09/2013
1	microtubule-associated protein 1B (MAP5)IBA 09/2013
1	ran-binding protein 2IBA 09/2013
1	Biological ProductsIBA 04/2013
1	Nuclear Proteins (Protein, Nuclear)IBA 07/2011
1	Serine (L-Serine)FDA Link 07/2011
1	Growth Differentiation Factor 1IBA 07/2010
1	EphrinsIBA 06/2006
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 06/2006
1	Growth Hormone (Somatotropin)IBA 05/2006
1	prolyl-proline (Pro-Pro)IBA 01/2006
1	prolyl-serine (Pro-Ser)IBA 01/2006
1	Checkpoint Kinase 2IBA 02/2005

Therapy/Procedure

3	Hysterectomy 01/2022 - 10/2014
1	Therapeutics 09/2013
1	Ligation 06/2008